EAD (TTM)

EAD/share (TTM)

EAD (Quarter)

EAD/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/EAD

Based in Westbury, NY, ACRES Commercial Realty Corp is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender exclusively dedicated to nationwide middle market CRE lending with a focus on multifamily, student housing, hospitality, office, industrial and other asset types in top US markets.

ACRES Commercial Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q1

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
EAD Growth: 6/15,
EAD/share Growth: 11/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's EAD

EAD Growth

Assessment of recent increases in EAD per share, indicating profitability

EAD/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

UNIONDALE, N.Y., April 15, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the first quarter 2026, on Wednesday, April 29, 2026, after the market closes.

ACRES Commercial Realty Corp. to Report Results for First Quarter 2026

Two Harbors Investments (NYSE: TWO - Get Free Report) and ACRES Commercial Realty (NYSE: ACR - Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 64.2%

Reviewing ACRES Commercial Realty (NYSE:ACR) and Two Harbors Investments (NYSE:TWO)

UNIONDALE, N.Y., March 19, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs)

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

ACRES Commercial Realty (NYSE: ACR - Get Free Report) and AGNC Investment (NASDAQ: AGNCZ - Get Free Report) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Recommendations This is a breakdown of

AGNC Investment (NASDAQ:AGNCZ) versus ACRES Commercial Realty (NYSE:ACR) Financial Review

UNIONDALE, N.Y., March 4, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter and year ended December 31, 2025.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2025 AND YEAR ENDED DECEMBER 31, 2025

ACR Alpine Capital Research, LLC increased its stake in Arrow Electronics by 1,028,778 shares. Quarter-end position value rose by approximately $87 million, reflecting both trading activity and stock price movement.

ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock

KKR Real Estate Finance Trust (NYSE: KREF - Get Free Report) and ACRES Commercial Realty (NYSE: ACR - Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Institutional and Insider

ACRES Commercial Realty (NYSE:ACR) versus KKR Real Estate Finance Trust (NYSE:KREF) Head-To-Head Contrast

UNIONDALE, N.Y., Feb. 18, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the fourth quarter 2025, on Wednesday, March 4, 2026, after the market closes.

ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2025

POTENT PRECLINICAL EFFICACY WITH DURABLE IMMUNE MEMORY OBSERVED IN COMBINATIONS OF EITHER ACR-368 OR ACR-2316 WITH ANTI-PD-L1 AND STRONG SYNERGY OF ACR-368 WITH TOPOISOMERASE 1 (TOPO 1) INHIBITION

ACRIVON TO HIGHLIGHT PRECLINICAL DATA WITH THREE POSTERS AT AACR DEMONSTRATING STRONG ACR-368 AND ACR-2316 SYNERGIES WITH IMMUNE CHECKPOINT INHIBITORS AND ADC PAYLOADS, REVEALING BROAD CLINICAL DEVELOPMENT OPPORTUNITIES

UNIONDALE, N.Y., APRIL 15, 2026 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT IT WILL RELEASE ITS RESULTS FOR THE FIRST QUARTER 2026, ON WEDNESDAY, APRIL 29, 2026, AFTER THE MARKET CLOSES.

ACRES COMMERCIAL REALTY CORP. TO REPORT RESULTS FOR FIRST QUARTER 2026

UNIONDALE, N.Y., MARCH 19, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP.(NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED CASH DIVIDENDS ON ITS PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. DECLARES QUARTERLY CASH DIVIDENDS FOR ITS PREFERRED STOCK

ACR-368, A CHK1/2 INHIBITOR IN A REGISTRATIONAL-INTENT PHASE 2B STUDY, SHOWED POTENT PRECLINICAL SYNERGY WITH TOPOISOMERASE 1 (TOPO 1) INHIBITORS, COMMONLY USED PAYLOADS IN ANTIBODY-DRUG CONJUGATES (ADCS)

ACRIVON THERAPEUTICS TO PRESENT PRE-CLINICAL AP3 DATA AT THE 2026 AACR ANNUAL MEETING REVEALING STRONG SYNERGY OF ACR-368 WITH ADC TOPO 1 INHIBITOR PAYLOADS AND OF BOTH ACR-368 AND ACR-2316 WITH IMMUNE CHECKPOINT INHIBITORS

UNIONDALE, N.Y., MARCH 4, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) ("ACR" OR THE "COMPANY"),A REAL ESTATE INVESTMENT TRUST THAT IS PRIMARILY FOCUSED ON ORIGINATING, HOLDING AND MANAGING COMMERCIAL REAL ESTATE MORTGAGE LOANS AND EQUITY INVESTMENTS IN COMMERCIAL REAL ESTATE PROPERTY THROUGH DIRECT OWNERSHIP AND JOINT VENTURES, TODAY REPORTED RESULTS FOR THE QUARTER AND YEAR ENDED DECEMBER31, 2025.

UNIONDALE, N.Y., FEB. 18, 2026 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT IT WILL RELEASE ITS RESULTS FOR THE FOURTH QUARTER 2025, ON WEDNESDAY, MARCH 4, 2026, AFTER THE MARKET CLOSES.

ACRES COMMERCIAL REALTY CORP. TO REPORT RESULTS FOR FOURTH QUARTER 2025

UNIONDALE, N.Y., JAN. 20, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) (THE "COMPANY") ANNOUNCED THAT ITS NEWLY FORMED SUBSIDIARY, ACRES COMMERCIAL REALTY 2026-FL4 ISSUER, LLC (THE "ISSUER") WILL ISSUE $879.5 MILLION OF NON-RECOURSE, FLOATING-RATE NOTES ("OFFERED NOTES," THE "SECURITIES" OR THE "OFFERING") AT A WEIGHTED-AVERAGE COST OF THE ONE-MONTH TERM SECURED OVERNIGHT FINANCING RATE ("SOFR")+168 BASIS POINTS.

ACRES COMMERCIAL REALTY CORP. ANNOUNCES PRICING OF A $1.0 BILLION CLO BACKED BY COMMERCIAL MORTGAGE LOANS

ELECTRONIC DATA CAPTURE (EDC) EXTRACT FROM THE ONGOING ACR-368 REGISTRATIONAL-INTENT PHASE 2B MONOTHERAPY TRIAL IN ONCOSIGNATURE-POSITIVE (BM+) SUBJECTS WITH ENDOMETRIAL CANCER (EC) SHOWED 39% OVERALL RESPONSE RATE (ORR) AND 44% IN SUBJECTS WITH 2 PRIOR LINES OF THERAPY* ANALYSIS OF DATA FROM ALL-COMER SUBJECTS WITH SEROUS SUBTYPE AND 2 PRIOR LINES OF THERAPY, A HIGH UNMET NEED POPULATION, SHOWED A CONFIRMED ORR (CORR) OF 52%, AND WITHIN BM+ SUBJECTS CORR WAS 67%, CONSISTENT WITH HIGHER BM LEVELS ACROSS SEROUS SUBJECTS ARM 3 IS ENROLLING UP TO 90 SUBJECTS WITH SEROUS SUBTYPE AND 2 PRIOR LINES OF THERAPY, WITHOUT REQUIREMENT FOR A TUMOR BIOPSY, FOR TREATMENT WITH ACR-368 PLUS ULTRA-LOW DOSE GEMCITABINE (ULDG) AS A TUMOR SENSITIZER AND ENROLLMENT COMPLETION EXPECTED IN FOURTH QUARTER 2026 BASED ON PRECLINICAL AP3 DATA SHOWING STRONG SYNERGY BETWEEN ACR-368 AND ANTI-PD-L1, COMPANY HAS SUBMITTED A PHASE 3 CONFIRMATORY PROTOCOL TO THE FDA FOR ACR-368 PLUS ANTI-PD-1 THERAPY IN FRONTLINE EC SUBJECTS; GLOBAL TRIAL READINESS EXPECTED MID-2026 INITIAL DATA FROM PHASE 1 DOSE ESCALATION (N=33) FOR ACR-2316, A POTENTIAL FIRST-IN-CLASS WEE1/PKMYT1 INHIBITOR, SHOWED FAVORABLE TOLERABILITY; TWO WEEKLY ORAL DOSING REGIMENS (160 MG QD, 3D ON/4D OFF AND 240 MG QD, 2D ON/5D OFF) ESTABLISHED WITH A BI-WEEKLY REGIMEN INITIATED TUMOR SHRINKAGE WAS OBSERVED AT 120 MG DOSE LEVEL IN 9/20 SUBJECTS, INCLUDING A CONFIRMED PR IN EC, AND UNCONFIRMED PRS IN SCLC AND SQNSCLC, TWO TUMOR TYPES PREDICTED SENSITIVE BY AP3, NOT PREVIOUSLY SHOWN SENSITIVE TO WEE1 INHIBITORS IN DEVELOPMENT ACR-6840, A POTENTIAL FIRST-IN-CLASS AP3-DERIVED ORAL CDK11 INHIBITOR, NOMINATED AS NEXT PRECLINICAL DEVELOPMENT CANDIDATE, WITH IND SUBMISSION PLANNED FOR FOURTH QUARTER 2026 COMPANY TO HOLD VIDEO CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET WATERTOWN, MASS.

ACRIVON THERAPEUTICS ANNOUNCES POSITIVE ACR-368 PHASE 2B ENDOMETRIAL CANCER CLINICAL DATA WITH EU EXPANSION TO ACCELERATE ENROLLMENT, INITIAL ACR-2316 CLINICAL DATA, AND ACR-6840, ITS NEXT AP3-ENABLED DEVELOPMENT CANDIDATE, TARGETING CDK11

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET ON THURSDAY, JANUARY 8, 2026 COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET ON THURSDAY, JANUARY 8, 2026

ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES VIA WEBCAST

WATERTOWN, MASS., DEC. 17, 2025 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (ACRIVON OR ACRIVON THERAPEUTICS) (NASDAQ: ACRV), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING PRECISION MEDICINES UTILIZING ITS PROPRIETARY GENERATIVE PHOSPHOPROTEOMICS AP3 (ACRIVON PREDICTIVE PRECISION PROTEOMICS) PLATFORM DESIGNED TO INTERPRET AND QUANTIFY GLOBAL COMPOUND-SPECIFIC, DRUG-REGULATED EFFECTS IN THE INTACT CELL WHICH IS DEPLOYED FOR RATIONAL DRUG DESIGN AND PREDICTIVE CLINICAL DEVELOPMENT, TODAY ANNOUNCED IT WILL BE PROVIDING ACR-368 AND ACR-2316 CLINICAL DATA AND OTHER UPDATES VIA A CONFERENCE CALL AND WEBCAST IN JANUARY 2026.

UPDATE -- ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES VIA WEBCAST

ACRES Commercial Realty

ACR

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR